Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Paramagnetic rim lesions predict the development of clinical MS in radiologically isolated syndrome: results from a prospective cohort study
Multiple Sclerosis
S27 - MS Neuroimaging (1:24 PM-1:36 PM)
003

We previously found that most pwRIS have high proportions of white matter lesions positive for the central vein sign (CVS+L) and at least one paramagnetic rim lesion (PRL), representing perivenular and chronic active demyelination, respectively. Whether PRL and CVS+L relate to the risk of developing clinical MS in pwRIS prospectively is unknown.

To determine the association of various MRI measures and subsequent development of clinical MS in people with radiologically isolated syndrome (pwRIS).

PwRIS were recruited prospectively and underwent 3T-MRI, including 3D-FLAIR and T2*segmented EPI of the brain, and sagittal T1-PSIR of the cervical spinal cord(SC). MRIs were evaluated for presence of PRL,CVS+L, and SC lesions (SCL).

36 pwRIS (median age 43 years, 70% women, median time of clinical follow-up 6.3 years) were included in the study. Clinical MS developed in 9 (25%) subjects with a median time to first clinical event of 5.2 years. 67% developed RRMS and 33% PPMS. At baseline, pwRIS who developed clinical MS vs those who did not had a higher median number of PRL (11 vs 1, p=0.01) and CVS+L(34 vs 10, p=0.04). Longitudinally, number of new brain lesions, PRL, CVS+L (all p<0.01) and SCL (p=0.02) were higher in those who subsequently developed clinical MS. Multivariable logistic regression using backward stepwise selection identified baseline PRL count as the most predictive variable of MS development among baseline and follow-up imaging measures (p=0.01).

In this prospective cohort of pwRIS, 25% developed MS within 5 years after initial diagnosis, with 33% diagnosed as PPMS. Baseline PRL count was the most predictive MRI measure for subsequent development of clinical MS in pwRIS, suggesting that PRLs may have prognostic utility. Continued follow-up of this cohort and validation in larger datasets will be important to confirm the clinical predictive value of PRL and CVS+L in pwRIS.

Authors/Disclosures
Jiwon Oh, MD, FAAN (St Michael's Hospital)
PRESENTER
Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from Roche.
Timothy R. Lim Timothy R. Lim has nothing to disclose.
Suradech Suthiphosuwan, MD (St Michael’s Hospital, Unity Health) Dr. Suthiphosuwan has nothing to disclose.
Adrian Isidoro Espiritu, MD (Ontario Shores Centre for Mental Health Sciences) Dr. Espiritu has nothing to disclose.
Melanie Guenette Melanie Guenette has nothing to disclose.
Aditya Bharatha, MD Dr. Bharatha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis.
Pascal Sati, PhD (Cedars Sinai) The institution of Dr. Sati has received research support from National Multiple Sclerosis Society. The institution of Dr. Sati has received research support from National Institutes of Health. Dr. Sati has received intellectual property interests from a discovery or technology relating to health care.
Martina Absinta, MD Dr. Absinta has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Absinta has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abata Therapeutics. The institution of Dr. Absinta has received research support from International MS Alliance. The institution of Dr. Absinta has received research support from FRRB Early Career Award. The institution of Dr. Absinta has received research support from Cariplo Foundation.
Daniel Reich, MD,PhD (National Institutes of Health, Neuroimmunology Branch, NINDS) Dr. Reich has received research support from NIH. The institution of Dr. Reich has received research support from Adelson Medical Research Foundation. The institution of Dr. Reich has received research support from Sanofi-Genzyme. The institution of Dr. Reich has received research support from Abata Therapeutics. The institution of Dr. Reich has received research support from National Multiple Sclerosis Society. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with PeerView. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with AcademicCME. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Integrity. Dr. Reich has a non-compensated relationship as a Advisor with Sanofi-Genzyme that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Board of Directors with ACTRIMS that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Abata Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with American Brain Foundation that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with University of Basel RC2NB that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Multiple Sclerosis Society of Canada that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Tuscan Doctorate in Neuroscience that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Editorial Board with Multiple Sclerosis Journal that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Biohaven that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Sana that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Merck KGaA EMD Serono that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Bristol-Meyers Squibb that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with ChemoCentryx that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Hyperfine that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Imaginab that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Perceptive that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Annexon that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Philips that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Siemens that is relevant to AAN interests or activities.